Lpath Announces Reverse Split of Class A Common Stock

Lpath Announces Reverse Split of Class A Common Stock 
Required to Complete NASDAQ Listing 
SAN DIEGO, CA -- (Marketwire) -- 10/04/12 --  Lpath, Inc. (OTCQB:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
announced a 1-for-7 reverse split of the company's issued and
outstanding Class A common stock and a corresponding decrease in the
number of its authorized shares of Class A common stock. The reverse
stock split will be effective as of 5:00 p.m. PDT on October 5, 2012. 
"We have elected to effect a reverse stock split to help Lpath meet
the listing requirements of the NASDAQ Capital Market," said Scott
Pancoast, president and chief executive officer of Lpath. "We believe
that a NASDAQ listing and the reverse stock split can broaden our
shareholder base and increase the appeal of our stock to
institutional investors. Further, these actions should provide
benefits to our shareholders by improving trading liquidity in the
stock, thereby enhancing long-term shareholder value." 
Each shareholder's percentage ownership interest in Lpath and the
proportional voting power remains unchanged after the reverse stock
split. In addition, the rights and privileges of the holders of our
common stock are unaffected by the reverse stock split. This reverse
stock split is pursuant to a Certificate of Change filed with the
State of Nevada.  
As of the effective date, every seven shares of issued and
outstanding common stock will be converted into one share of common
stock, with all fractional shares being rounded up to the nearest
whole share. The reverse stock split will reduce the number of shares
of issued and outstanding Class A common stock from approximately
73.7 million pre-split to approximately 10.5 million post-split. The
number of authorized shares of Class A common stock will be reduced
from 200.0 million to 28.6 million. Proportional adjustments will be
made to Lpath's warrants, stock options, and equity-compensation
plans. The reverse stock split will have no effect on the company's
authorized shares of preferred stock. 
The company's common stock will trade under a new CUSIP number
(548910306). The company's ticker symbol will remain unchanged,
although a "D" will be placed on the LPTN ticker symbol (LPTND) for
20 business days to alert the public about the reverse stock split. 
It is not necessary for shareholders of the company to exchange their
existing stock certificates for new stock certificates of the company
in connection with the reverse stock split, although shareholders may
do so if they wish. Please direct any questions you might have
concerning the reverse stock split to your broker or the company's
transfer agent, Nevada Agency and Transfer Company, at (775)
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics, an
emerging field of medicine that targets bioactive signaling lipids
for treating a wide range of human disease. Lpath's ImmuneY2(TM)
drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute
to disease. The company has developed three drug candidates:
iSONEP(TM) is currently in a Phase 2 trial for wet AMD; ASONEP(TM)
will soon begin a Phase 2 trial in Renal Cell Carcinoma patients; and
Lpathomab is a preclinical drug candidate that holds promise in pain,
neurotrauma, and other diseases. Lpath entered into an agreement with
Pfizer Inc. (NYSE: PFE) in 2010 that provides Pfizer an exclusive
option for a worldwide license to develop and commercialize iSONEP.
For more information, visit www.Lpath.com. 
About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description
of historical facts are forward-looking statements. These include
statements regarding: the Company's ability to qualify to list its
shares of Class A common stock on the NASDAQ Capital Market and the
potential benefits and impact of the reverse stock split and a
listing on the NASDAQ Capital Market. Actual results may differ
materially from those set forth in this press release due to the
risks and uncertainties inherent in the Company's business,
including, without limitation: the results of the Company's
pre-clinical testing and its clinical trials may not support either
further clinical development or the commercialization of its drug
candidates; the Company may not successfully complete additional
clinical trials for its product candidates on a timely basis, or at
all; none of the Company's drug candidates have received regulatory
approval at this time, and the Company may fail to obtain required
governmental approvals for its drug candidates; the Company has a
history of net losses and may never achieve or maintain
profitability; the Company may not be successful in maintaining its
commercial relationship with Pfizer Inc.; the Company may not be able
to secure the funds necessary to support its preclinical- and
clinical-development plans and the Company may not be successful in
qualifying to list its shares of Class A common stock on the NASDAQ
Capital Market. More detailed information about the Company and the
risk factors that may affect the realization of forward-looking
statements is set forth in the Company's filings with the Securities
and Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q filed with the SEC. Such documents
may be read free of charge on the SEC's web site at www.sec.gov. You
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200
Lpath Investor Relations
Liolios Group, Inc. (949) 574-3860
Ron Both: ron@liolios.com 
Geoffrey Plank: geoffrey@liolios.com 
Press spacebar to pause and continue. Press esc to stop.